1. The Safety and Efficacy of the Combination of Sacituzumab Govitecan and Palliative Radiotherapy—A Retrospective Multi-Center Cohort Study.
- Author
-
Krug, David, Tio, Joke, Abaci, Ali, Beurer, Björn, Brügge, Sandra, Elsayad, Khaled, Meixner, Eva, Park-Simon, Tjoung-Won, Smetanay, Katharina, Winkelmann, Franziska, Wittig, Andrea, and Wöckel, Achim
- Subjects
THERAPEUTIC use of antineoplastic agents ,THERAPEUTIC use of monoclonal antibodies ,PALLIATIVE treatment ,PATIENT safety ,HORMONE receptor positive breast cancer ,RESEARCH funding ,BREAST tumors ,IMMUNOGLOBULINS ,TREATMENT effectiveness ,RETROSPECTIVE studies ,RADIOSURGERY ,METASTASIS ,LONGITUDINAL method ,SYSTEMATIC reviews ,DRUG efficacy ,RESEARCH ,MEDICAL records ,ACQUISITION of data ,EVALUATION - Abstract
Simple Summary: Sacituzumab govitecan is an antibody–drug conjugate that has been approved for the treatment of metastatic triple-negative breast cancer and, recently, also for metastatic hormone receptor-positive HER2-negative breast cancer. Although patients with metastatic breast cancer frequently need palliative radiotherapy, none of the published prospective trials studied the combination of radiotherapy and Sacituzumab govitecan. We conducted a multi-center retrospective cohort study to assess the efficacy and safety of Sacituzumab govitecan and palliative radiotherapy. We did not find signs of increased toxicity, and response rates were favorable despite extensive prior treatment. More research is necessary to determine the optimal integration of novel systemic agents and radiotherapy in the palliative setting. Sacituzumab govitecan (SG) is a new treatment option for patients with metastatic triple-negative and hormone receptor-positive, HER2-negative breast cancer. This antibody–drug conjugate is currently approved as monotherapy. Palliative radiotherapy is frequently used to treat symptomatic metastases locally. Concurrent use of SG and irradiation was excluded in clinical trials of SG, and there are currently limited published data. We report here a systematic review, as well as a retrospective multi-center study of 17 patients with triple-negative breast cancer who received concurrent SG and radiotherapy. In these patients, concurrent use was found to be efficient, safe and well tolerated. There were no apparent differences in moderate or severe acute toxicity according to the timing of SG administration. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF